Erratum: Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells (Proceedings of the National Academy of Sciences of the United Stated of America (2010) 106 (3919-3924) DOI: 10.1073/pnas.0809516106));Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 10, 2009, Pages 3919-3924

  Ford, Caroline E ^a,b   Ekström, Elin J ^a   Andersson, Tommy ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Breast cancer; ER

Indexed keywords

CASPASE 3; ESTROGEN RECEPTOR ALPHA; FOXY 5 PEPTIDE; HEXAPEPTIDE; PROGESTERONE RECEPTOR; PROTEIN PS2; TAMOXIFEN; UNCLASSIFIED DRUG; WNT3A PROTEIN; WNT5A PROTEIN;

4T1 CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN T47D; CONTROLLED STUDY; CYTOLYSIS; DNA METHYLATION; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; HUMAN; HUMAN CELL; MDA MB 231 CELL; MDA MB 468 CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 62649157723     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1017549108     Document Type: Erratum

References (42)

1. Giacinti L, Claudio PP, Lopez M, Giordano A (2006) Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11:1-8.
2. Jö nsson M, Dejmek J, Bendahl PO, Andersson T (2002) Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 62:409-416.
3. Dejmek J, et al. (2005) Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res 11:520-528.
4. Leandersson K, Riesbeck K, Andersson T (2006) Wnt-5a mRNA translation is suppressed by the Elav-like protein HuR in human breast epithelial cells. Nucleic Acids Res 34:3988-3999.
5. Dejmek J, Dejmek A, Säfholm A, Sjölander A, Andersson T (2005) Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 65:9142-9146.
6. Liu XH, et al. (2008) Expression of Wnt-5a and its clinicopathological significance in hepatocellular carcinoma. Digest Liver Dis 40:560-567.
7. Weeraratna AT, et al. (2002) Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1:279-288.
8. Jönsson M, Andersson T (2001) Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J Cell Sci 114:2043-2053.
9. Dejmek J, Säfholm A, Kamp Nielsen C, Andersson T, Leandersson K (2006) Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42- casein kinase 1alpha signaling in human mammary epithelial cells. Mol Cell Biol 26:6024-6036.
10. Säfholm A, et al. (2006) A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J Biol Chem 281:2740-2749.
11. Säfholm A, et al. (2008) A Wnt-5a-derived hexapeptide F5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res 14:6556-6563.
12. Sharma D, et al. (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19:1740-1751.
13. Bandyopadhyay A, Wang L, Chin SH, Sun LZ (2007) Inhibition of skeletal metastasis by ectopic ERalpha expression in ERalpha-negative human breast cancer cell lines. Neoplasia 9:113-118.
14. Jang ER, et al. (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23:1724-1736.
15. Sharma D, Saxena NK, Davidson NE, Vertino PM (2006) Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 66:6370-6378.
16. Bruserud O, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A (2007) Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 8:388-400.
17. Witt O, Deubzer HE, Milde T, & Oehme I (2008) HDAC family: What are the cancer relevant targets? Cancer Lett doi:10.1016/j.canlet. 2008.08.016.
18. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90.
19. Lapidus RG, et al. (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2:805-810.
20. Leader JE, Wang C, Fu M, Pestell RG (2006) Epigenetic regulation of nuclear steroid receptors. Biochem Pharmacol 72:1589-1596.
21. Green S, et al. (1986) Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320:134-139.
22. Murphy LC, Niu Y, Snell L, Watson P (2004) Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clin Cancer Res 10:5902-5906.
23. Zoubir M, et al. (2008) Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol 19:1402-1406.
24. Chen D, et al. (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21:4291-4931.
25. Howell A (2006) Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr-Relat Cancer 13:689-706.
26. Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89:4037-4041.
27. Dauvois S, White R, & Parker MG (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388.
28. Fawell SE, et al. (1990) Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87:6883-6887.
29. Foekens JA, et al. (1990) Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50:3832-3837.
30. Johnston SRD, Dowsett M (2003) Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer 3:821-831.
31. Gelman E (1996) Tamoxifen induction of apoptosis in estrogen receptor-neagtive cancers: New tricks for an old dog? J Natl Cancer I 88:224-226.
32. Zheng A, Kallio A, Härkönen P (2007) Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology 148:2764-2777.
33. Janicke RU (2008) MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat DOI 10.1007/s10549-008-0217-9.
34. Curtis CD, Likhite VS, McLeod IX, Yates JR, Nardulli AM (2007) Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor alpha alters estrogen-responsive gene expression. Cancer Res 67:10600-10607.
35. Suzuki T, et al. (2001) EBAG9/RCAS1 in human breast carcinoma: A possible factor in endocrine-immune interactions. Br J Cancer 85:1731-1737.
36. Tsuchiya F, et al. (2001) Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. Biochem Biophys Res Commun 284:2-10.
37. Kuiper GG, et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 863-870.
38. Ottaviano YL, et al. (1994) Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54:2552-2555.
39. Schambony A, Kunz M, Gradl D (2004) Cross-regulation of Wnt signaling and cell adhesion. Differentiation 72:307-318.
40. Mikels AJ, Nusse R (2006) Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 4:e115. doi:10.1371/journal.pbio.0040115.
41. Dissanayake SK, et al. (2007) The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 282:17259-17271.
42. Li C, et al. (2008) Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol 9:11. doi: 10.1186/1471-2199-9-11.